

# Secrétariat scientifique

Ces publications 2024 témoignent bien du dynamisme et de la grande diversité de la recherche au Centre Oscar Lambret, avec la valorisation de travaux en oncologie médicale, radiothérapie et radiophysique, chirurgie carcinologique, pédiatrie, mais aussi sciences humaines et sociales.

Les publications sont réparties par Domaines. Les publications à l'initiative du COL sont précédées par \*\*\*.

## Publications COL 2024

### Sarcomes

Poumeaud F, Valentin T, Fares N, Segier B, Watson S, Verret B, Tlemsani C, Penel N, Lejeune S, Firmin N, Sabouret A, They JC, Bonvalot S, Cottreau E, Cauchin E, Lancon A, Nambot S, Zattara H, Coudert M, Fourme E, Nogues C, Tougeron D, Prieur F, Collonge-Rame MA, Denis C, Laurent-Puig P, Chieze-Valero S, Dreyfus H, Jaffrelot M, Vande Perre P, Rochaix P, Gomez-Mascard A, Rochefort P, Campoy S, Chibon F, Lasset C, Selves J, Guimbaud R.

Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy.

Eur J Cancer. 2024 Dec 21;216:115196. doi: 10.1016/j.ejca.2024.115196.

\*\*\* Noeueglise M, Tessier W, Barthoulot M, Decanter G, Cayeux A, Marin H, Lemoine-Gobert P, Aymes E, Taieb S, Fayard C, Beaujot J, Robin YM, Lartigau EF, Penel N, Cordoba A.

Preoperative versus postoperative radiotherapy for localized soft tissue sarcoma treated with curative intent in a French tertiary center "SARCLOC".

BMC Cancer. 2024 Dec 18;24(1):1550. doi: 10.1186/s12885-024-13243-0.

Colombo C, Hakkesteegt S, Le Cesne A, Barretta F, Blay JY, Grünhagen DJ, Penel N, Lam L, Fiore M, Palassini E, Grignani G, Tolomeo F, Collini P, Merlini A, Perrone F, Stacchiotti S, Verhoef C, Bonvalot S, Gronchi A. Active surveillance in patients with extra-abdominal desmoid-type fibromatosis: a pooled analysis of three prospective observational studies.

Clin Cancer Res. 2024 Dec 2. doi: 10.1158/1078-0432.CCR-24-2340.

Srouf E, Martin N, Drullion C, De Schutter C, Giroud J, Pioger A, Deslé J, Saas L, Nassour J, Théry J, Decanter G, Penel N, Vercamer C, Salazar-Cardozo C, Abbadie C, Pluquet O.

Prostaglandin E2 regulates senescence and post-senescence neoplastic escape in primary human keratinocytes. Aging (Albany NY). 2024 Nov 18;16(21):13201-13224. doi: 10.18632/aging.206149.

Blay JY, Schiffler C, Bouché O, Brahmi M, Duffaud F, Toulmonde M, Landi B, Lahlou W, Pannier D, Bompas E, Bertucci F, Chaigneau L, Collard O, Pracht M, Henon C, Ray-Coquard I, Armoun K, Salas S, Spalato-Ceruso M, Adenis A, Verret B, Penel N, Moreau-Bachelard C, Italiano A, Dufresne A, Metzger S, Chabaud S, Perol D, Le Cesne A.

A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.

Ann Oncol. 2024 Dec;35(12):1157-1168. doi: 10.1016/j.annonc.2024.08.2343.

Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Le Cesne A, Balleyguier C, Archambaud B, Duffaud F; French Sarcoma Group.

Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.  
N Engl J Med. 2024 Sep 5;391(9):789-799. doi: 10.1056/NEJMoa2403394.

Cuenin M, Levy A, Peiffert D, Sunyach MP, Ducassou A, Cordoba A, Gillon P, Thibouw D, Lapeyre M, Lerouge D, Helfre S, Leroux A, Salleron J, Sirveaux F, Marchal F, P Teixeira, Debordes PA, G Vogin.  
Local relapse patterns after preoperative radiotherapy of limb and trunk wall soft tissue sarcomas: Prognostic role of imaging and pathologic response factors.  
Clin Transl Radiat Oncol. 2024 Jul 26;48:100825. doi: 10.1016/j.ctro.2024.100825.

Blay JY, Devin Q, Duffaud F, Toulmonde M, Firmin N, Collard O, Bompas E, Verret B, Ray-Coquard I, Salas S, Henon C, Honoré C, Brahmi M, Dufresne A, Pracht M, Hervieu A, Penel N, Bertucci F, Rios M, Saada-Bouزيد E, Soibinet P, Perol D, Chabaud S, Italiano A, Cesne AL.  
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.  
Lancet Oncol. 2024 Sep;25(9):1163-1175. doi: 10.1016/S1470-2045(24)00318-8.

Blay JY, Penel N, Toulmonde M, Valentin T, Chaigneau L, Rios M, Saada-Bouزيد E, Firmin N, Bertucci F, Marec-Berard P, Ray-Coquard I, Lervat C, Rolland F, Thyss A, Conroy T, Brahmi M, Dufresne A, Merrouche Y, Brunat-Mentigny M, Biron P, Bompas E, Perol D; French Sarcoma Group.  
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO.  
Eur J Cancer. 2024 Sep;208:114228. doi: 10.1016/j.ejca.2024.114228.

Kasper B, Baldini EH, Bonvalot S, Callegaro D, Cardona K, Colombo C, Corradini N, Crago AM, Dei Tos AP, Dileo P, Elnekave E, Erinjeri JP, Navid F, Farma JM, Ferrari A, Fiore M, Gladdy RA, Gounder M, Haas RL, Husson O, Kurtz JE, Lazar AJ, Orbach D, Penel N, Ratan R, Raut CP, Roland CL, Schut AW, Sparber-Sauer M, Strauss DC, Van der Graaf WTA, Vitellaro M, Weiss AR, Gronchi A; Desmoid Tumor Working Group.  
Current Management of Desmoid Tumors: A Review.  
JAMA Oncol. 2024 Aug 1;10(8):1121-1128. doi: 10.1001/jamaoncol.2024.1805.

Tuan HX, Tuan TA, Tam NT, Cong HD, Duy NQ, Hung ND, Ceugnart L, Duc NM.  
An infrequent case of retroperitoneal synovial sarcoma.  
Radiol Case Rep. 2024 May 31;19(8):3456-3460. doi: 10.1016/j.radcr.2024.05.029.

Huchet N, Penel N, Bonvalot S, Thariat J, Ducimetière F, Giraud A, Toulmonde M, Le Cesne A, Blay JY, Bellera C.  
Handling missing covariates in observational studies: an illustration with the assessment of prognostic factors of survival outcomes in soft-tissue or visceral sarcomas in irradiated fields (SIF).  
Ther Adv Med Oncol. 2024 Jan 19;16:17588359231220999. doi: 10.1177/17588359231220999.

Blay JY, Penel N, Valentin T, Anract P, Duffaud F, Dufresne A, Verret B, Cordoba A, Italiano A, Brahmi M, Henon C, Amouyel T, Ray-Coquard I, Ferron G, Boudou-Rouquette P, Tlemsani C, Salas S, Rochwerger R, Faron M, Bompas E, Ducassou A, Gangloff D, Gouin F, Firmin N, Piperno-Neumann S, Rios M, Ropars M, Kurtz JE, Le Nail LR, Bertucci F, Carrere S, Llacer C, Watson S, Bonvalot S, Leroux A, Perrin C, Gantzer J, Pracht M, Narciso B, Monneur A, Lebbe C, Hervieu A, Saada-Bouزيد E, Dubray-Longeras P, Fiorenza F, Chaigneau L, Nevieres ZM, Soibinet P, Bouché O, Guillemet C, Spano JP, Ruzic JC, Isambert N, Vaz G, Meeus P, Karanian M, Ngo C, Coindre JM, De Pinieux G, Le Loarer F, Ducimetiere F, Chemin C, Morelle M, Toulmonde M, Le Cesne A.  
Improved nationwide survival of sarcoma patients with a network of reference centers.  
Ann Oncol. 2024 Apr;35(4):351-363. doi: 10.1016/j.annonc.2024.01.001.

Blay JY, Tlemsani C, Toulmonde M, Italiano A, Rios M, Bompas E, Valentin T, Duffaud F, Le Nail LR, Watson S, Firmin N, Dubray-Longeras P, Ropars M, Perrin C, Hervieu A, Lebbe C, Saada-Bouزيد E, Soibinet P, Fiorenza F, Bertucci F, Boudou P, Vaz G, Bonvalot S, Honoré C, Marec-Berard P, Minard V, Cleirec M, Biau D, Meeus P, Babinet A, Dumaine V, Carriere S, Fau M, Decanter G, Gouin F, Ngo C, Le Loarer F, Karanian M, Meurgey A, Dufresne A, Brahmi M, Chemin-Airiau C, Ducimetiere F, Penel N, Le Cesne A;

NETSARC/REPPS/RESOS and French Sarcoma Group- Groupe d'Etude des Tumeurs Osseuses (GSF-GETO) networks.

Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years.

Eur J Cancer. 2024 Jan;196:113454. doi: 10.1016/j.ejca.2023.113454.

## Gynécologie

Classe JM, Meeus P, Hudry D, Wernert R, Quenet F, Marchal F, Houvenaeghel G, Bats AS, Lecuru F, Ferron G, Brigand C, Berton D, Gladieff L, Joly F, Ray-Coquard I, Durand-Fontanier S, Liberale G, Pocard M, Georgeac C, Gouy S, Guilloit JM, Guyon F, Costan C, Rousselet JM, de Guerké L, Bakrin N, Brument E, Martin E, Asselain B, Champion L, Glehen O; UNICANCER/CHIPOR Investigators.

Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial.

Lancet Oncol. 2024 Dec;25(12):1551-1562. doi: 10.1016/S1470-2045(24)00531-X.

Becker O, Durand A, Chevrier M, Collet L, Gladieff L, Joly F, Sauterey B, Pomel C, Costaz H, Pautier P, Guillemet C, de la Motte Rouge T, Sabatier R, Classe JM, Petit T, Leblanc E, Marchal F, Colombo PE, Barranger E, Savoye AM, Bosquet L, Ray-Coquard I, Carton M, Colomban O, You B, Rodrigues M.

Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas.

Int J Gynecol Cancer. 2025 Jan 6:ijgc-2024-005815. doi: 10.1136/ijgc-2024-005815.

Ka K, Cordoba A, Cagetti LV, Schiappa R, Kissel M, Escande A, Casabianca LG, Buchalet C, Gouy S, Morice P, Narducci F, Martinez C, Jauffret C, Lambaudie E, Delpech Y, Laas E, Gaillard T, Hannoun-Levi JM, Espenel S, Chargari C.

Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group.

Gynecol Oncol. 2024 Sep;188:90-96. doi: 10.1016/j.ygyno.2024.06.010.

\*\*\* Cordoba A, El Hajj H, Escande A, Scouarnec C, Narducci F, Martinez Gomez C, Leblanc E, Hudry D, Pasquesoone C, Taieb S, Mirabel X, Lartigau EF, Le Tinier F.

Intermediate-risk endometrial cancer treated with adjuvant brachytherapy using single dosimetric planning: long-term outcome and toxicity assessment.

Eur J Obstet Gynecol Reprod Biol. 2024 Jul;298:23-30. doi: 10.1016/j.ejogrb.2024.04.040.

\*\*\* Lambaudie E, Bogart E, Le Deley MC, El Hajj H, Gauthier T, Hebert T, Collinet P, Classe JM, Lecuru F, Motton S, Conri V, Ferrer C, Marchal F, Ferron G, Probst A, Jauffret C, Narducci F.

The Influence of Surgical Complexity and Center Experience on Postoperative Morbidity After Minimally Invasive Surgery in Gynecologic Oncology: Lessons Learned from the ROBOGYN-1004 Trial.

Ann Surg Oncol. 2024 Jul;31(7):4566-4575. doi: 10.1245/s10434-024-15265-1.

Gouin F, Michot A, Jafari M, Honoré C, Mattei JC, Rochwerger A, Ropars M, Tzanis D, Anract P, Carrere S, Gangloff D, Ducoulombier A, Lebbe C, Guiramand J, Waast D, Marchal F, Sirveaux F, Causeret S, Gimbergues P, Fiorenza F, Paquette B, Soibinet P, Guilloit JM, Le Nail LR, Dujardin F, Brinkert D, Chemin-Airiau C, Morelle M, Meeus P, Karanian M, Le Loarer F, Vaz G, Blay JY; NETSARC/RREPS and French Sarcoma Group-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO) Networks.

Improved Metastatic-Free Survival after Systematic Re-Excision Following Complete Macroscopic Unplanned Excision of Limb or Trunk Soft Tissue Sarcoma.

Cancers (Basel). 2024 Mar 30;16(7):1365. doi: 10.3390/cancers16071365.

\*\*\* Cordoba A, Gesta E, Escande A, Noeuvéglise A, Cayez R, Halty A, Ladjimi MT, Narducci F, Hudry D, Martinez Gomez C, Cordoba S, Le Deley MC, Barthoulot M, Lartigau EF.

Interstitial needles versus intracavitary applicators only for locally advanced cervical cancer: results from real-life dosimetric comparisons.

Front Oncol. 2024 Mar 19;14:1347727. doi: 10.3389/fonc.2024.1347727.

Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, Selle F, Abdeddaim C, Leary A, Dubot-Poitelon C, Fabbro M, Gladiëff L, Lamuraglia M.

Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.

Nat Commun. 2024 Mar 5;15(1):1985. doi: 10.1038/s41467-024-45974-w. Erratum in: Nat Commun. 2024 Jun 4;15(1):4753. doi: 10.1038/s41467-024-48915-9.

Bizzarri N, Obermair A, Hsu HC, Chacon E, Collins A, Tsibulak I, Mutombo A, Abu-Rustum NR, Balaya V, Buda A, Cibula D, Covens A, Fanfani F, Ferron G, Frumovitz M, Guani B, Kocian R, Kohler C, Leblanc E, Lecuru F, Leitao MM Jr, Mathevet P, Mueller MD, Papadia A, Pareja R, Plante M, Querleu D, Scambia G, Tanner E, Zapardiel I, Garcia JR, Ramirez PT.

Consensus on surgical technique for sentinel lymph node dissection in cervical cancer.

Int J Gynecol Cancer. 2024 Apr 1;34(4):504-509. doi: 10.1136/ijgc-2023-005151.

Mokarram Dorri N, Del M, Cannone F, Lefebvre M, Loaec C, Sabiani L, Jauffret C, Blache G, Houvenaeghel G, Carcopino X, Classe JM, Narducci F, Martinez A, Lambaudie E.

Is minimally invasive surgical approach a reasonable option in apparent early stage epithelial ovarian cancer restaging? Results from a multicentric retrospective study.

Eur J Surg Oncol. 2024 Mar;50(3):107976. doi: 10.1016/j.ejso.2024.107976.

\*\*\* Montesinos-Albert M, Giroux PA, Hudry D, Pasquesoone C, Narducci F, Martinez-Gomez C.

Complex abdominal wall reconstruction for an isolated parietal recurrence of ovarian cancer.

Int J Gynecol Cancer. 2024 Feb 5;34(2):344-345. doi: 10.1136/ijgc-2023-004855.

Classe JM, Frenel JS, Berton D, Gladiëff L, Ferron G, Lecuru F, Bourgin C, Narducci F, Loaec C.

État des lieux des résultats en termes de survie de la CHIP en primo-traitement et en récurrence dans le cancer épithélial de l'ovaire [State of results of HIPEC for epithelial ovarian cancer in the primary treatment or for relapse].

Bull Cancer. 2024 Mar;111(3):261-266. doi: 10.1016/j.bulcan.2023.01.019.

## **Pédiatrie/AJA**

Filser M, Torrejon J, Merchadou K, Dufour C, Girard E, Bourneix C, Lemaître E, Gharsalli T, Brillet R, Wong J, Gentien D, Rapinat A, Servant N, Vasiljevic A, Bertozzi AI, Raimbault S, Tauziede Espariat A, Lhermitte B, Faure-Contier C, Icher C, Berger C, Maurage CA, Bodet D, Meyronet D, Uro-Coste E, De Carli E, Forest F, Palenzuela G, Chotard G, Gauchotte G, Sudour H, Mansuy L, Deparis M, Tallegas M, Faisant M, Entz-Werle N, Varlet P, Leblond P, Michalak-Provost S, Proust Houdemont S, Rigau V, Doz F, Delattre O, Bourdeaut F, Ayrault O, Masliah-Planchon J.

Nanopore Sequencing as a Cutting-Edge Technology for Medulloblastoma Classification.

Neuro Oncol. 2024 Dec 28;noae279. doi: 10.1093/neuonc/noae279.

Sevrin F, Bogart E, Orbach D, Le Deley MC, Berlanga P, Bernier V, Corradini N, Fayard C, Guerin F, Jannier S, Karanian M, Proust S, Rome A, Verité C, Minard-Colin V, Defachelles AS.

Therapy and Outcomes of Patients with Relapsed Nonmetastatic Rhabdomyosarcoma: A Report from the French Society of Pediatric Oncology Malignant Mesenchymal Tumor Committee.

Cancer Med. 2024 Dec;13(23):e70420. doi: 10.1002/cam4.70420.

Berlanga P, Aerts I, Corradini N, Ndounga-Diakou LA, Entz-Werle N, Ducassou S, André N, Sevrin F, Chastagner P, Puisseux C, Cleirec M, Plantaz D, De Carli E, Gambart M, Khanfar C, Thouvenin S, Petit A, Klein S, Briandet C, Millot F, Pluchart C, Reguerre Y, Schneider P, Serre J, Halfon-Domenech C, Carausu L, Piguet C, Saumet L, Benadiba J, Abbou S, Laghouati S, Geoerger B, Vassal G.

Centralized Investigator Review of Radiological and Functional Imaging Reports in Real-World Oncology

Studies: The SACHA-France Experience.  
Pediatr Blood Cancer. 2025 Feb;72(2):e31449. doi: 10.1002/psc.31449.

Kasprowicz A, Cavdarli S, Delannoy P, Le Guezennec X, Defebvre C, Spriet C, Jonckheere N, Le Doussal JM, Krzewinski-Recchi MA, Mitra S, Meignan S, Groux-Degroote S.  
Anti-OAcGD2 antibody in combination with ceramide kinase inhibitor mediates potent antitumor cytotoxicity against breast cancer and diffuse intrinsic pontine glioma cells.  
Mol Cell Biochem. 2024 Oct 12. doi: 10.1007/s11010-024-05127-5.

Huchede P, Meyer S, Berthelot C, Hamadou M, Bertrand-Chapel A, Rakotomalala A, Manceau L, Tomine J, Lespinasse N, Lewandowski P, Cordier-Bussat M, Broutier L, Dutour A, Rochet I, Blay JY, Degletagne C, Attignon V, Montero-Carcaboso A, Le Grand M, Pasquier E, Vasiljevic A, Gilardi-Hebenstreit P, Meignan S, Leblond P, Ribes V, Cosset E, Castets M.  
BMP2 and BMP7 cooperate with H3.3K27M to promote quiescence and invasiveness in pediatric diffuse midline gliomas.  
Elife. 2024 Oct 7;12:RP91313. doi: 10.7554/eLife.91313.

Poiree M, Gofiti-Laroche L, Riberon C, Leblond P, Laurence V, Gaspar N, Cordoba A, Lervat C, Maréc-Berard P.  
A Review of GO-AJA's Impact on Adolescents and Young Adults with Cancer in France: A Decade of Progress and Challenges.  
J Adolesc Young Adult Oncol. 2024 Sep 26. doi: 10.1089/jayao.2024.0020.

Sudour-Bonnange H, van Tinteren H, Ramírez-Villar GL, Godzinski J, Irtan S, Gessler M, Chowdhury T, Audry G, Fuchs J, Powis M, van de Ven CP, Okoye B, Smeulders N, Vujanic GM, Verschuur A, L'Herminé-Coulomb A, de Camargo B, de Aguirre Neto JC, Schenk JP, van den Heuvel-Eibrink MM, Pritchard-Jones K, Graf N, Bergeron C, Furtwängler R.  
Characteristics and outcome of synchronous bilateral Wilms tumour in the SIOP WT 2001 Study: Report from the SIOP Renal Tumour Study Group (SIOP-RTSG).  
Br J Cancer. 2024 Oct;131(6):972-981. doi: 10.1038/s41416-024-02799-0.

Choderlos de Laelos X, Risbourg S, Brennan B, Bertucci F, Gaspar N, Gelderblom H, Hawkins DS, Janeway K, Juergens H, Kasper B, Krailo MD, Le Deley MC, Marec-Bérard P, McCabe MG, Metzler M, Ranft A, Strauss S, Tabone MD, Windsor R, Dirksen U, Gandemer V.  
Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials.  
Eur J Cancer. 2024 Sep;208:114229. doi: 10.1016/j.ejca.2024.114229.

\*\*\* Poutrain E, Abelé-Naveau M, Baltora M, Villain A, Sakji I, Strobbe G, Marliot G.  
Securing the oral and enteral oncopediatric chemotherapy process in pediatric oncology: Introduction of the ENFit™ standard in a controlled-atmosphere area and implementation of a dispensing service of medications to outpatients circuit with advice on proper use.  
J Oncol Pharm Pract. 2024 Apr 13:10781552241241062. doi: 10.1177/10781552241241062.

Fuentes C, Ouldbe Y, Orbach D, Sudour-Bonnange H, Verité C, Rome A, Dumesnil C, Thebaud E, Hameury F, Dijoud F, Chabaud S, Cote MD, Fresneau B, Faure-Conter C.  
Oncological and endocrinological outcomes for children and adolescents with testicular and ovarian sex cord-stromal tumors. Results of the TGM13 National Registry.  
Pediatr Blood Cancer. 2024 Apr;71(4):e30864. doi: 10.1002/psc.30864.

\*\*\* André N, Le Deley MC, Léguillette C, Probst A, Willems L, Travers R, Aerts I, Faure-Conter C, Revond-Riviere G, Min V, Georger B, Chastagner P, Entz-Werlé N, Leblond P.  
METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors.  
Eur J Cancer. 2024 Feb;198:113525. doi: 10.1016/j.ejca.2024.113525.

Audinot B, Drubay D, Gaspar N, Mohr A, Cordero C, Marec-Bérard P, Lervat C, Piperno-Neumann S, Jimenez M, Mansuy L, Castex MP, Revon-Riviere G, Marie-Cardine A, Berger C, Piguët C, Massau K, Job B, Moquin-Beaudry G, Le Deley MC, Tabone MD, Berlanga P, Brugières L, Crompton BD, Marchais A, Abbou S. ctDNA quantification improves estimation of outcomes in patients with high-grade osteosarcoma: a translational study from the OS2006 trial. *Ann Oncol.* 2024 Jun;35(6):559-568. doi: 10.1016/j.annonc.2023.12.006.

Gatz SA, Harttrampf AC, Brard C, Bautista F, André N, Abbou S, Rubino J, Rondof W, Deloger M, Rübsam M, Marshall LV, Hübschmann D, Nebchi S, Aerts I, Thebaud E, De Carli E, Defachelles AS, Paoletti X, Godin R, Miah K, Mortimer PGS, Vassal G, Georger B. Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial. *Clin Cancer Res.* 2024 Feb 16;30(4):741-753. doi: 10.1158/1078-0432.CCR-23-2959.

Desandes E, Lapouble E, Lacour B, Guissou S, Goujon S, Defachelles AS, Marechal V, Gaspar N, Gomez-Mascard A, Karanian M, Marec-Berard P, Minard-Colin V, Orbach D, Tabone MD, Delattre O, Pierron G. Impact of age on survival according to molecular tumor findings in children and adolescents with soft-tissue and bone sarcoma: The BIOSCA project. *Cancer Epidemiol.* 2024 Oct;92:102398. doi: 10.1016/j.canep.2023.102398.

Givone A, Duval-Destin J, Delebarre M, Abou-Chahla W, Lervat C, Dubos F. Consensus survey on the management of children with chemotherapy-induced febrile neutropenia and at low risk of severe infection. *Pediatr Hematol Oncol.* 2024;41(2):172-178. doi: 10.1080/08880018.2023.2218406.

## Sénologie

\*\*\* Hego F, Barthoulot M, Chretien S, Pierard C, Boulaire M, Bécourt S, Boulanger L, Ceugnart L, Conoy AL, Oca F, Mailliez A. Breast Cancer Prognosis in Young BRCA1/BRCA2 Mutation Carriers: A Retrospective Hospital-based Cohort Study. *Clin Oncol (R Coll Radiol).* 2025 Jan;37:103658. doi: 10.1016/j.clon.2024.10.030.

Houvenaeghel G, Classe JM, Chauvet MP, Colombo PE, Jouve E, Reyat F, Daraï E, Rouzier R, Faure-Virelizier C, Gimbergues P, Coutant C, Mazouni C, Azuar AS, Martino M, Bouteille C, Cohen M, de Nonneville A. Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery. *Cancers (Basel).* 2024 Sep 27;16(19):3317. doi: 10.3390/cancers16193317.

Poumeaud F, Morisseau M, Cabel L, Gonçalves A, Rivier C, Trédan O, Volant E, Frenel JS, Ladoire S, Jacot W, Jamelot M, Foka Tichoue H, Patsouris A, Teixeira L, Bidard FC, Loirat D, Brunet M, Levy C, Bailleux C, Cabarrou B, Deleuze A, Uwer L, Deluche E, Grellety T, Franchet C, Fiteni F, Bischoff H, Vion R, Pagliuca M, Verret B, Bécourt S, Reverdy T, de Nonneville A, Dalenc F. Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer. *Br J Cancer.* 2024 Sep;131(4):702-708. doi: 10.1038/s41416-024-02766-9.

Sandoval JL, Franzoi MA, di Meglio A, Ferreira AR, Viansone A, André F, Martin AL, Everhard S, Jouannaud C, Fournier M, Rouanet P, Vanlemmens L, Dhaini-Merimeche A, Sauterey B, Cottu P, Levy C, Stringhini S, Guessous I, Vaz-Luis I, Menvielle G. Magnitude and Temporal Variations of Socioeconomic Inequalities in the Quality of Life After Early Breast Cancer: Results From the Multicentric French CANTO Cohort. *J Clin Oncol.* 2024 Aug 20;42(24):2908-2917. doi: 10.1200/JCO.23.02099.

Soldato D, Michiels S, Havas J, Di Meglio A, Pagliuca M, Franzoi MA, Pistilli B, Iyengar NM, Cottu P,

Lerebours F, Coutant C, Bertaut A, Tredan O, Vanlemmens L, Jouannaud C, Hrab I, Everhard S, Martin AL, André F, Vaz-Luis I, Jones LW.

Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer.

J Clin Oncol. 2024 Sep 1;42(25):3022-3032. doi: 10.1200/JCO.23.01959.

\*\*\* François C, Mailliez A, Chretien S, Leguillette C, Oudoux A, Ceugnart L, Barthoulot M, Cougnenc O, Olivier A.

Therapeutic impact of 18F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer.

Breast Cancer Res Treat. 2024 Oct;207(3):551-559. doi: 10.1007/s10549-024-07386-8.

Azim HA Jr, Niman SM, Partridge AH, Demeestere I, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz-Borrego M, Moore HCF, Saunders C, Bjelic-Radusic V, Susnjar S, Cardoso F, Klar NJ, Spanic T, Ruddy K, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Peccatori FA.

Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy.

J Clin Oncol. 2024 Aug 10;42(23):2822-2832. doi: 10.1200/JCO.23.02292.

Petit T, Hajjaji N, Antoine EC, Benderra MA, Gozy M, Foa C, Mouysset JL, Grenier J, Mousseau M, Mailliez A, Saghatchian M, Lachaier E, Desmoulins I, Hennequin A, Maes P, Loirat D, Ricci F, Diéras V, Berton D, Tiong FL, Teixeira L, Dohollou N, Lévy C, Bachelot T, Pierga JY.

Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.

Cancer Med. 2024 May;13(9):e7168. doi: 10.1002/cam4.7168.

Epaillard N, Lusque A, Jacot W, Mailliez A, Bachelot T, Arnedos M, Le Du F, Brain E, Ferrero JM, Massard V, Desmoulins I, Mouret-Reynier MA, Levy C, Gonçalves A, Leheurteur M, Petit T, Filleron T, Bosquet L, Pistilli B, Frenel JS.

Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort.

ESMO Open. 2024 May;9(5):103447. doi: 10.1016/j.esmoop.2024.103447.

Penault-Llorca F, Dalenc F, Chabaud S, Cottu P, Allouache D, Cameron D, Grenier J, Venat Bouvet L, Jegannathen A, Campone M, Debled M, Hardy-Bessard AC, Giacchetti S, Barthelemy P, Kaluzinski L, Mailliez A, Mouret-Reynier MA, Legouffe E, Cayre A, Martinez M, Delbaldo C, Mollon-Grange D, Macaskill EJ, Sephton M, Stefani L, Belgadi B, Winter M, Orfeuvre H, Lacroix-Triki M, Bonnefoi H, Bliss J, Canon JL, Lemonnier J, Andre F, Bachelot T.

Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.

ESMO Open. 2024 May;9(5):103443. doi: 10.1016/j.esmoop.2024.103443.

Frenel JS, Zeghondy J, Guérin-Charbonnel C, Mailliez A, Volant E, Poumeaud F, Patsouris A, Arnedos M, Bailleux C, Cabal J, Galland L, de Nonneville A, Guiu S, Dalenc F, Pistilli B, Bachelot T, Pierga JY, Le Du F, Bocquet F, Larrouquere L, Loirat D.

Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.

JAMA Netw Open. 2024 Apr 1;7(4):e244435. doi: 10.1001/jamanetworkopen.2024.4435.

Galvin A, Courtinard C, Bouteiller F, Gourgou S, Dalenc F, Jacot W, Arnedos M, Bailleux C, Dieras V, Petit T, Emile G, Dubray-Longeras P, Frenel JS, Bachelot T, Mailliez A, Brain E, Desmoulins I, Massard V, Patsouris A, Goncalves A, Grinda T, Delalogue S, Bellera C.

First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.

Eur J Cancer. 2024 Jan;196:113422. doi: 10.1016/j.ejca.2023.113422.

## Essais de phase précoce

Rodon J, Prenen H, Sacher A, Villalona-Calero M, Penel N, El Helali A, Rottey S, Yamamoto N, Ghiringhelli F, Goebeler ME, Doi T, Postel-Vinay S, Lin CC, Liu C, Chuang CH, Keyvanjah K, Eggert T, O'Neil BH. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration. *Ann Oncol.* 2024 Dec;35(12):1138-1147. doi: 10.1016/j.annonc.2024.08.2339.

Belmontes B, Slemmons KK, Su C, Liu S, Policheni AN, Moriguchi J, Tan H, Xie F, Aiello DA, Yang Y, Lazaro R, Aeffner F, Rees MG, Ronan MM, Roth JA, Vestergaard M, Cowland S, Andersson J, Sarvary I, Chen Q, Sharma P, Lopez P, Tamayo N, Pettus LH, Ghimire-Rijal S, Mukund S, Allen JR, DeVoss J, Coxon A, Rodon J, Ghiringhelli F, Penel N, Prenen H, Glad S, Chuang CH, Keyvanjah K, Townsley DM, Butler JR, Bourbeau MP, Caenepeel S, Hughes PE. AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers. *Cancer Discov.* 2025 Jan 13;15(1):139-161. doi: 10.1158/2159-8290.CD-24-0887.

## VADS

Giraud P, Guihard S, Thureau S, Guilbert P, Ruffier A, Eugene R, Lamrani-Ghaoui A, Chargari C, Liem X, Bibault JE. Prediction of the need of enteral nutrition during radiation therapy for head and neck cancers. *Radiother Oncol.* 2024 Dec 21;203:110693. doi: 10.1016/j.radonc.2024.110693.

Louison J, Labreuche J, Liem X, Rysman B, Morisse M, Mortuaire G, Mouawad F. Voice quality after surgery or radiotherapy for glottic T1 squamous cell carcinoma: Results of the VOQUAL study. *Cancer Radiother.* 2024 Aug;28(4):373-379. doi: 10.1016/j.canrad.2024.03.004. Erratum in: *Cancer Radiother.* 2024 Dec;28(8):727. doi: 10.1016/j.canrad.2024.09.001.

\*\*\* Tonneau M, Roos M, Cayez R, Wagner A, Leguillette C, Le Deley MC, Lals S, Martinage G, Pasquier D, Mirabel X, Lacornerie T, Liem X. Multicriteria optimization of radiation therapy: Towards empowerment and standardization of reverse planning for head and neck squamous cell carcinoma. *Cancer Radiother.* 2024 Aug;28(4):317-322. doi: 10.1016/j.canrad.2024.01.003.

Liem X, de Baère T, Vivar OI, Seiwert TY, Shen C, Pápai Z, Moreno V, Takácsi-Nagy Z, Helfferich F, Thariat J, Gooi Z, Yom SS, Bossi P, Ferris RL, Hackman TG, Le Tourneau C, Rodriguez J, Hoffmann C. International guidelines for intratumoral and intranodal injection of NBTXR3 nanoparticles in head and neck cancers. *Head Neck.* 2024 Jun;46(6):1253-1262. doi: 10.1002/hed.27739.

Guillemin F, Blanchard P, Boisselier P, Brahimi Y, Calugaru V, Coutte A, Gillon P, Graff P, Liem X, Modesto A, Pointreau Y, Racadot S, Sun XS, Bellini R, Pham Dang N, Saroul N, Bourhis J, Thariat J, Biau J, Lapeyre M. Proposition de délimitation des volumes cibles anatomocliniques postopératoires de la tumeur primitive des cancers du sinus maxillaire et des cavités nasales [Proposal for the delineation of postoperative primary clinical target volumes in maxillary sinus and nasal cavity cancers]. *Cancer Radiother.* 2024 Apr;28(2):218-227. doi: 10.1016/j.canrad.2023.12.001.

Barry B, Dolivet G, Clatot F, Huguet F, Abdeddaim C, Baujat B, Blanchard N, Calais G, Carrat X, Chatellier A, Coste F, Cupissol D, Cuvelier P, De Mones Del Pujol E, Deneuve S, Duffas O, Dupret-Bories A, Even C, Evrard C, Evrard D, Faivre S, Fakhry N, Garrel R, Gorphe P, Houliat T, Kaminsky MC, Krebs L, Lapeyre M, Lindas P, Malard O, Mirghani H, Mondina M, Moriniere S, Mouawad F, Pestre-Munier J, Pham Dang N, Picard A, Ramin L, Renard S, Salvan D, Schernberg A, Sire C, Thariat J, Vanbockstael J, Vo Tan D, Wojcik T, Klein I, Block V, Baumann-Bouscaud L, De Raucourt D.



Référentiel national de traitement des carcinomes épidermoïdes des voies aérodigestives supérieures – Principes généraux de traitement [French national standard for the treatment of squamous cell carcinoma of upper aerodigestive tract - General principles of treatment].

Bull Cancer. 2024 Apr;111(4):393-415. doi: 10.1016/j.bulcan.2023.12.007.

Dolivet G, Barry B, Abdeddaim C, Baujat B, Blanchard N, Calais G, Carrat X, Chatellier A, Clatot F, Coste F, Cupissol D, Cuvelier P, de Mones Del Pujol E, Deneuve S, Duffas O, Dupret-Bories A, Even C, Evrard C, Evrard D, Faivre S, Fakhry N, Garrel R, Gorphe P, Houliat T, Huguet F, Kaminsky MC, Krebs L, Lapeyre M, Lindas P, Malard O, Mirghani H, Mondina M, Moriniere S, Mouawad F, Pestre-Munier J, Pham Dang N, Picard A, Ramin L, Renard S, Salvan D, Schernberg A, Sire C, Thariat J, Vanbockstael J, Vo Tan D, Wojcik T, Klein I, Block V, Baumann-Bouscaud L, de Raucourt D.

Référentiel national de traitement des carcinomes épidermoïdes des voies aérodigestives supérieures [National standard for the treatment of squamous cell carcinoma of upper aerodigestive tract].

Bull Cancer. 2024 Apr;111(4):327-332. doi: 10.1016/j.bulcan.2023.08.015.

Perrier L, Balusson F, Morelle M, Castelli J, Thariat J, Benezery K, Hasbini A, Gery B, Berger A, Liem X, Guihard S, Chapet S, Thureau S, Auberdiaac P, Pommier P, Ruffier A, Devillers A, Oger E, Campillo-Gimenez B, de Crevoisier R.

Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial.

Radiother Oncol. 2024 Apr;193:110116. doi: 10.1016/j.radonc.2024.110116.

\*\*\* Delerue C, Pasquier D, Bogart E, Mirabel X, Laffarguette J, Lals S, Barthoulot M, Lartigau E, Liem X. Stereotactic reirradiation in the treatment of head and neck cancers: A retrospective study on the long-term experience of the Oscar Lambret Center.

Radiother Oncol. 2024 Jan;190:110029. doi: 10.1016/j.radonc.2023.110029.

Hes C, Desilets A, Tonneau M, El Ouarzadi O, De Figueiredo Sousa M, Bahig H, Filion É, Nguyen-Tan PF, Christopoulos A, Benlaïfaoui M, Derosa L, Alves Costa Silva C, Ponce M, Malo J, Belkad W, Charpentier D, Aubin F, Hamilou Z, Jamal R, Messaoudene M, Soulières D, Routy B.

Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma.

Oral Oncol. 2024 Jan;148:106623. doi: 10.1016/j.oraloncology.2023.106623.

Tonneau M, Nebbache R, Larnaudie A, Thureau S, Pointreau Y, Blanchard P, Thariat J.

Management of head and neck carcinomas with synchronous or metachronous oligometastatic disease: Role of locoregional radiotherapy and metastasis-directed radiotherapy.

Cancer Radiother. 2024 Feb;28(1):83-92. doi: 10.1016/j.canrad.2023.03.004.

## Digestif

Cotte E, Arquilliere J, Artru P, Bachet JB, Benhaim L, Bibeau F, Christou N, Conroy T, Doyen J, Hoeffel C, Meillan N, Mirabel X, Pioche M, Rivin Del Campo E, Vendrely V, Huguet F, Bouché O; Thésaurus National de Cancérologie Digestive (TNCD) (Société Nationale Française de Gastroentérologie (SNFGE); Fédération Francophone de Cancérologie Digestive (FFCD); Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Société Française de Chirurgie Digestive (SFCD); Société Française d'Endoscopie Digestive (SFED); Société Française de Radiothérapie Oncologique (SFRO); Association de Chirurgie Hépatobiliaire-Pancréatique et Transplantation (ACHBT); Société Française de Pathologie (SFP); Réseau National de Référence des Tumeurs Rares du Péritoine (RENAPE); Société Nationale Française de Colo-Proctologie (SNFCP); Association Française pour l'Étude du Foie (AFEF); Société Française de Radiologie (SFR)); GRECCAR (Groupe de Recherche Chirurgicale sur la Cancer du Rectum).

Rectal cancer - French intergroup clinical practice guidelines for diagnosis, treatment, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF,

SFR, and GRECCAR).

Dig Liver Dis. 2024 Dec 17;S1590-8658(24)01117-4. doi: 10.1016/j.dld.2024.12.004.

Fumet JD, Roussot N, Bertaut A, Limagne E, Thibaudin M, Hervieu A, Zanetta S, Borg C, Senellart H, Pernot S, Thuillier F, Carnot A, Mineur L, Chibaudel B, Touchefeu Y, Martin-Babau J, Jary M, Labourey JL, Rederstorff E, Lepage C, Ghiringhelli F.

Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer. *Future Oncol.* 2024;20(38):3077-3085. doi: 10.1080/14796694.2024.2415280.

Collard MK, Mineur L, Nekrouf C, Denost Q, Rouanet P, de Chaisemartin C, Merdrignac A, Jafari M, Cotte E, Desrame J, Manceau G, Benoist S, Buscail E, Karoui M, Panis Y, Piessen G, Saudemont A, Prudhomme M, Peschaud F, Dubois A, Loriau J, Tuech JJ, Duchalais E, Lupinacci R, Goasgen N, Simon T, Parc Y, Lefevre JH; French Research Group of Rectal Cancer Surgery (GRECCAR).

Final Results of the GRECCAR-6 Trial on Waiting Period Following Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer: 5 Years of Follow-up.

*Dis Colon Rectum.* 2024 Nov 7. doi: 10.1097/DCR.0000000000003477

\*\*\* Strobbe G, Jeanjacquot M, Potey C, Carnot A, Marliot G.

Grade 3 cytolysis in a patient with metastatic colorectal cancer consuming a mushroom powder-based alternative therapy.

*J Oncol Pharm Pract.* 2024 Sep 2:10781552241280617. doi: 10.1177/10781552241280617.

Trilling B, Tidadini F, Lakkis Z, Jafari M, Germain A, Rullier E, Lefevre J, Tuech JJ, Kartheuser A, Leonard D, Prudhomme M, Piessen G, Regimbeau JM, Cotte E, Duprez D, Badic B, Panis Y, Rivoire M, Meunier B, Portier G, Bosson JL, Vilotitch A, Foote A, Caspar Y, Rouanet P, Faucheron JL; GRECCAR study Group.

Suprapubic versus transurethral catheterization for bladder drainage in male rectal cancer surgery (GRECCAR10), a randomized clinical trial.

*Tech Coloproctol.* 2024 Jul 2;28(1):77. doi: 10.1007/s10151-024-02950-2.

\*\*\* Tailleux A, Roquette I.

Radiothérapie stéréotaxique hépatique [Stereotactic radiation therapy for liver tumours].

*Rev Med Liege.* 2024 May;79(S1):20-25.

Kato K, Doki Y, Chau I, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Makino T, Blum Murphy M, Amaya-Chanaga C, Patel A, Hu N, Matsumura Y, Kitagawa Y, Ajani J.

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.

*Cancer Med.* 2024 May;13(9):e7235. doi: 10.1002/cam4.7235.

Kim S, Ghiringhelli F, de la Fouchardière C, Evesque L, Smith D, Badet N, Samalin E, Lopez-Trabada Ataz D, Parzy A, Desramé J, Baba Hamed N, Buecher B, Tougeron D, Bouché O, Dahan L, Chibaudel B, El Hajbi F, Mineur L, Dubreuil O, Ben Abdelghani M, Pecout S, Bibeau F, Herfs M, Garcia ML, Meurisse A, Vernerey D, Taïeb J, Borg C.

Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.

*Lancet Oncol.* 2024 Apr;25(4):518-528. doi: 10.1016/S1470-2045(24)00081-0.

\*\*\* De Metz C, Hennart B, Aymes E, Cren PY, Martignène N, Penel N, Barthoulot M, Carnot A.

Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study.

*Cancer Med.* 2024 Mar;13(6):e7066. doi: 10.1002/cam4.7066.

Ningarhari M, Bertez M, Ploquin A, Bertrand N, Desauw C, Cattan S, Catala P, Vandamme H, Cheymol C, Truant S, Lassailly G, Louvet A, Mathurin P, Dharancy S, Turpin A.

Conventional cytotoxic chemotherapy for gastrointestinal cancer in patients with cirrhosis: A multicentre case-

control study.

Liver Int. 2024 Mar;44(3):682-690. doi: 10.1111/liv.15813.

Ajani J, El Hajbi F, Cunningham D, Alsina M, Thuss-Patience P, Scagliotti GV, Van den Eynde M, Kim SB, Kato K, Shen L, Li L, Ding N, Shi J, Barnes G, Van Cutsem E.

Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study.

ESMO Open. 2024 Jan;9(1):102202. doi: 10.1016/j.esmoop.2023.102202.

Huguet F, Riou O, Pasquier D, Modesto A, Quéro L, Michalet M, Bordron A, Schipman B, Orthuon A, Lisbona A, Vendrely V, Jaksic N.

Radiation therapy of the primary tumour and/or metastases of digestive metastatic cancers.

Cancer Radiother. 2024 Feb;28(1):66-74. doi: 10.1016/j.canrad.2023.04.007.

Bae SH, Chun SJ, Chung JH, Kim E, Kang JK, Jang WI, Moon JE, Roquette I, Mirabel X, Kimura T, Ueno M, Su TS, Tree AC, Guckenberger M, Lo SS, Scorsetti M, Slotman BJ, Kotecha R, Sahgal A, Louie AV, Kim MS. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines.

Int J Radiat Oncol Biol Phys. 2024 Feb 1;118(2):337-351. doi: 10.1016/j.ijrobp.2023.08.015.

## **Pneumologie**

Walter T, Lecomte T, Hadoux J, Niccoli P, Saban-Roche L, Gaye E, Guimbaud R, Baconnier M, Hautefeuille V, Do Cao C, Petorin C, Hentic O, Perrier M, Aparicio T, Scoazec JY, Bonjour M, Gibert B, Hervieu V, Poncet D, Barritault M, Gerard L, Durand A; “Groupe d’étude des tumeurs endocrines (GTE)” and the French ENDOCAN-RENATEN network.

Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET).

J Clin Oncol. 2024 Nov 25;JCO2302724. doi: 10.1200/JCO.23.02724.

Cabart M, Mourey L, Pasquier D, Schneider S, Léna H, Girard N, Chouaid C, Schott R, Huret S, Debieuvre D, Quantin X, Madroszyk A, Dubray-Longeras P, Pichon E, Baranzelli A, Justeau G, Pérol M, Bosquet L, Cabarrou B.

Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database.

J Geriatr Oncol. 2024 Sep;15(7):101819. doi: 10.1016/j.jgo.2024.101819.

Baudin E, Capdevila J, Hörsch D, Singh S, Caplin ME, Wolin EM, Buikhuisen W, Raderer M, Dansin E, Grohe C, Ferone D, Houchard A, Truong-Thanh XM, Reidy-Lagunes D.

Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.

Endocr Relat Cancer. 2024 Jul 22;31(9):e230337. doi: 10.1530/ERC-23-0337.

Thomas QD, Quantin X, Lemercier P, Chouaid C, Schneider S, Filleron T, Remon-Masip J, Perol M, Debieuvre D, Audigier-Valette C, Justeau G, Loeb A, Huret S, Clement-Duchene C, Dansin E, Stancu A, Pichon E, Bosquet L, Girard N, Du Rusquec P.

Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort.

ESMO Open. 2024 Jun;9(6):103473. doi: 10.1016/j.esmoop.2024.103473.

Basse C, Khalifa J, Thillays F, Le Pechoux C, Maury JM, Bonte PE, Coutte A, Pourel N, Bourbonne V, Pradier O, Belliere A, Le Tinier F, Deberne M, Tanguy R, Denis F, Padovani L, Zaccariotto A, Molina T, Chalabreysse L, Brioude G, Delatour B, Faivre JC, Cao K, Giraud P, Riet FG, Thureau S, Antoni D, Massabeau C, Keller A, Bonnet E, Lerouge D, Martin E, Girard N, Botticella A.

Recommendations for Post-Operative RadioTherapy After Complete Resection of Thymoma-a French

DELPHI Consensus Initiative.

J Thorac Oncol. 2024 Jul;19(7):1095-1107. doi: 10.1016/j.jtho.2024.04.003.

Goudet P, Cadiot G, Barlier A, Baudin E, Borson-Chazot F, Brunaud L, Caiazzo R, Cardot-Bauters C, Castinetti F, Chanson P, Cuny T, Dansin E, Gaujoux S, Giraud S, Groussin L, Le Bras M, Lifante JC, Mathonnet M, de Mestier L, Mirallié E, Pattou F, Romanet P, Sebag F, Tresallet C, Vezzosi D, Walter T, Tabarin A.

French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d'étude des Tumeurs Endocrines/Association Francophone de Chirurgie Endocrinienne/Reseau national de prise en charge des tumeurs endocrines) for the screening, diagnosis and management of Multiple Endocrine Neoplasia Type 1.

Ann Endocrinol (Paris). 2024 Feb;85(1):2-19. doi: 10.1016/j.ando.2023.09.003.

## Urologie

\*\*\* Brassart C, Coutte A, Wallet J, Meyer E, Benyoucef A, Mnif H, Kowalski V, Barthoulot M, Pasquier D. Oncological outcomes of patients with muscle-invasive bladder cancer treated with trimodal strategy: A French multicentric study.

Cancer Radiother. 2024 Dec;28(8):657-666. doi: 10.1016/j.canrad.2024.05.005.

Gueiderikh A, Baude J, Baron D, Schiappa R, Katsahian S, Moreau D, Laurans M, Bibault JE, Kreps S, Bondiau PY, Quivrin M, Lépinoy A, Pasquier D, Hannoun-Levi JM, Giraud P.

Nodal radiotherapy for prostate adenocarcinoma recurrence: predictive factors for efficacy.

Front Oncol. 2024 Oct 25;14:1468248. doi: 10.3389/fonc.2024.1468248.

Sweis RF, Gajate P, Morales-Barrera R, Lee JL, Necchi A, de Braud F, Penel N, Grünwald V, Maruzzo M, Meran J, Ishida TC, Bao W, Zhou Y, Ellinghaus P, Rosenberg JE.

Rogartatinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial.

JAMA Oncol. 2024 Nov;10(11):1565-1570. doi: 10.1001/jamaoncol.2024.3900.

Saint F, Pasquier D, Villers A, Massa J, Colin P, Vankemmel O, Leroy X, Bonnal JL, Plouvier SD.

Incidence, initial management and survival of high-risk non-muscle invasive bladder cancer in Northern France.

Fr J Urol. 2024 Sep;34(9):102675. doi: 10.1016/j.fjurol.2024.102675.

Le Guevelou J, Cuccia F, Flippot R, Ferrera G, Terlizzi M, Zilli T, De Crevoisier R, Hannoun-Levi JM, Supiot S, Sargos P, Pasquier D.

The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer.

Prostate Cancer Prostatic Dis. 2024 Jun 19. doi: 10.1038/s41391-024-00862-8.

Boué-Raflé A, Briens A, Supiot S, Blanchard P, Baty M, Lafond C, Masson I, Créhange G, Cosset JM, Pasquier D, de Crevoisier R.

La radiothérapie du cancer de la prostate augmente-t-elle le risque de seconds cancers ? [Does radiation therapy for prostate cancer increase the risk of second cancers?].

Cancer Radiother. 2024 Jun;28(3):293-307. French. doi: 10.1016/j.canrad.2023.07.018.

Naffrichoux J, Poupin P, Pouillot W, Linassier C, Rioux-Leclercq N, De Vries-Brilland M, Mourey L, Laguerre B, Oudard S, Gross-Goupil M, Mousset C, Gravis G, Rolland F, Moise L, Emambux S, Vassal C, Zanetta S, Penel N, Albiges L, Fromont G, Cancel M.

PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.

Eur J Cancer. 2024 Jul;205:114121. doi: 10.1016/j.ejca.2024.114121.

Marvaso G, Jereczek-Fossa BA, Zaffaroni M, Vincini MG, Corrao G, Andratschke N, Balagamwala EH, Bedke J, Blanck O, Capitanio U, Correa RJM, De Meerleer G, Franzese C, Gaeta A, Gandini S, Garibaldi C, Gerszten PC, Gillissen S, Grubb WR, Guckenberger M, Hannan R, Jhaveri PM, Josipovic M, Kerkmeijer LGW, Lehrer EJ, Lindskog M, Louie AV, Nguyen QN, Ost P, Palma DA, Procopio G, Rossi M, Staehler M, Tree AC, Tsang YM, Van As N, Zaorsky NG, Zilli T, Pasquier D, Siva S.

Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology.

Lancet Oncol. 2024 May;25(5):e193-e204. doi: 10.1016/S1470-2045(24)00023-8.

Plouvier SD, Marcq G, Vankemmel O, Colin P, Bonnal JL, Leroy X, Saint F, Pasquier D.

Practice patterns and survival outcomes for muscle-invasive bladder cancer: real-life experience in a general population setting.

Int J Qual Health Care. 2024 May 18;36(2):mzae040. doi: 10.1093/intqhc/mzae040.

\*\*\* Galienne M, Risbourg S, Lacornerie T, Taillez A, Lartigau E, Barthoulot M, Pasquier D.

Extreme hypofractionated stereotactic radiotherapy for localized prostate Cancer: Efficacy and late urinary

toxicity according to transurethral resection of the prostate history.  
Clin Transl Radiat Oncol. 2024 Apr 18;46:100779. doi: 10.1016/j.ctro.2024.100779.

Coquan E, Penel N, Lequesne J, Leman R, Lavaud P, Neviere Z, Brachet PE, Meriaux E, Carnot A, Boutrois J, Castera M, Goardon N, Muller E, Leconte A, Thiery-Vuillemin A, Clarisse B, Joly F.  
Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial.  
Ther Adv Urol. 2024 Feb 28;16:17562872241229876. doi: 10.1177/17562872241229876.

Baron D, Pasquier D, Pace-Loscos T, Vandendorpe B, Schiappa R, Ortholan C, Hannoun-Levi JM.  
Stereotactic body radiation therapy to postpone systemic therapy escalation for castration-resistant prostate cancer: A multicenter retrospective analysis.  
Clin Transl Radiat Oncol. 2023 Dec 8;45:100710. doi: 10.1016/j.ctro.2023.100710.

Baron D, Pasquier D, Pace-Loscos T, Vandendorpe B, Schiappa R, Ortholan C, Hannoun-Levi JM.  
Response to "Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients - A closer inspection will improve your vision".  
Clin Transl Radiat Oncol. 2024 Feb 21;46:100755. doi: 10.1016/j.ctro.2024.100755.

Latorzeff I, Camps-Maléa A, Supiot S, de Crevoisier R, Farcy-Jacquet MP, Hannoun-Lévi JM, Riou O, Pommier P, Artignan X, Chapet O, Créhange G, Marchesi V, Pasquier D, Sargos P.  
Indication and perspectives of radiation therapy in the setting of de-novo metastatic prostate cancer.  
Cancer Radiother. 2024 Feb;28(1):49-55. doi: 10.1016/j.canrad.2023.05.004.

Le Guevelou J, Sargos P, Ferretti L, Supiot S, Pasquier D, Créhange G, Blanchard P, Hennequin C, Chapet O, Schick U, Baty M, Masson I, Ploussard G, De Crevoisier R, Latorzeff I.  
Sexual Structure Sparing for Prostate Cancer Radiotherapy: A Systematic Review.  
Eur Urol Oncol. 2024 Jun;7(3):332-343. doi: 10.1016/j.euo.2023.08.003.

Colomba E, Jonas SF, Eymard JC, Delva R, Brachet PE, Neuzillet Y, Penel N, Roubaud G, Bompas E, Mahammedi H, Longo R, Helisse C, Barthélemy P, Borchiellini D, Hasbini A, Priou F, Saldana C, Voog E, Narcisso B, Ladoire S, Berdah JF, Aisenfarb JB, Foulon S, Fizazi K.  
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.  
Eur Urol. 2024 Mar;85(3):274-282. doi: 10.1016/j.eururo.2023.05.009.

## **Algologie, Médecine Palliative & Soins de Support**

Baudry AS, Delpuech M, Charton E, Peugniez C, Hivert B, Carnot A, Ceban T, Dominguez S, Lemaire A, Aelbrecht-Meurisse C, Anota A, Christophe V.  
Is intrapersonal emotional competence a personal resource for the quality of life of informal caregivers of cancer patients unlike interpersonal emotional competence?  
Qual Life Res. 2024 Nov 20. doi: 10.1007/s11136-024-03833-7.

\*\*\* Adenis A, Da Silva A, Ben Abdelghani M, Bourgeois V, Bogart E, Turpin A, Evin A, Proux A, Galais MP, Jaraudias C, Quintin J, Bouquet G, Samalin E, Bremaud N, Javed S, Henry A, Kurtz JE, Cornuault-Foubert D, Vandamme H, Lucchi E, Pannier D, Belletier C, Paul M, Touzet L, Penel N, Chvetzoff G, Le Deley MC.  
Early palliative care and overall survival in patients with metastatic upper gastrointestinal cancers (EPIC): a multicentre, open-label, randomised controlled phase 3 trial.  
EClinicalMedicine. 2024 Jun 28;74:102470. doi: 10.1016/j.eclinm.2024.102470.

Baudry AS, Charton E, Hivert B, Carnot A, Ceban T, Dominguez S, Lemaire A, Aelbrecht-Meurisse C, Christophe V.  
Supportive care needs and anxious-depressive symptoms in cancer patients: An interaction effect between

emotional competence and the COVID-19 pandemic?

Appl Psychol Health Well Being. 2024 Nov;16(4):1716-1730. doi: 10.1111/aphw.12552.

Baudry AS, Delpuech M, Charton E, Hivert B, Carnot A, Ceban T, Dominguez S, Lemaire A, Aelbrecht-Meurisse C, Anota A, Christophe V.

Association between emotional competence and risk of unmet supportive care needs in caregivers of cancer patients at the beginning of care.

Support Care Cancer. 2024 Apr 22;32(5):302. doi: 10.1007/s00520-024-08510-6.

\*\*\* Laurent EMN, Ducrocq C, Cren PY, Boutaa K, Crie D, Penel N.

Why do second-cycle medical students choose oncology? A literature overview.

Bull Cancer. 2024 May;111(5):505-512. doi: 10.1016/j.bulcan.2024.02.003.

\*\*\* Penel N, Mailliez A, Pannier D, Ducrocq C.

Doit-on prendre en compte le stress informationnel de l'oncologue médical ? [Should we take into account the informational stress of the medical oncologist?].

Bull Cancer. 2024 Feb;111(2):222-227. doi: 10.1016/j.bulcan.2023.11.008.

Rubenstrunk A, Gagez AL, Hoesler CH, Demol E, Mahieux I, Lavedrine F, Raff F, Vuylsteke J, Mazure J, Lecouffe R.

Pediatric Palliative Care for a French Hospital-At-Home Facility: A Case Report.

J Pediatr Health Care. 2024 Jan-Feb;38(1):90-96. doi: 10.1016/j.pedhc.2023.07.005.

\*\*\* Garcia V, Wallet J, Leroux-Bromberg N, Delbrouck D, Hannebicque K, Ben Oune F, Léguillette C, Le Deley MC, Ahmeidi A.

Incidence and characteristics of chronic postsurgical pain at 6 months after total mastectomy under pectoserratus and interpectoral plane block combined with general anesthesia: a prospective cohort study.

Reg Anesth Pain Med. 2024 Jan 11;49(1):36-40. doi: 10.1136/rapm-2022-104185.

Luporsi E, Turpin A, Massard V, Morin S, Chauffert B, Carnot A, Cacoub P; Behalf of the CARENFER Study Group.

Iron deficiency in patients with cancer: a prospective cross-sectional study.

BMJ Support Palliat Care. 2024 May 17;14(2):215-221. doi: 10.1136/bmjspcare-2021-002913.

## **Radiothérapie, Radiophysique**

Andratschke N, Willmann J, Appelt AL, Day M, Kronborg C, Massacesi M, Ozsahin M, Pasquier D, Petric P, Riesterer O, De Ruyscher D, M Van der Velden J, Guckenberger M.

Reirradiation - still navigating uncharted waters?

Clin Transl Radiat Oncol. 2024 Oct 2;49:100871. doi: 10.1016/j.ctro.2024.100871.

Haaser T, Constantinides Y, Osman D, Lahmi L, Durdux C, Bourbonne V, Cheval V, de Crevoisier R, Dejean C, Ducteil A, Escande A, Gesbert C, Ghannam Y, Lemanski C, Thureau S, Lagrange JL, Huguet F; Commission éthique de la Société française de radiothérapie oncologique (SFRO).

Survenue d'un évènement ou d'une erreur en oncologie radiothérapie : concilier les perspectives pour préserver le soin [Events and errors in radiation oncology: Conciliating perspectives to support care].

Cancer Radiother. 2024 Nov;28(6-7):527-533. French. doi: 10.1016/j.canrad.2024.07.017.

Smahi A, Lakhali O, Chettibi T, Sanz Lopez M, Pasquier D, Merzouki R.

Adaptive approach for tracking movements of biological targets: application to robot-based intervention for prostate cancer.

Front Robot AI. 2024 Aug 12;11:1416662. doi: 10.3389/frobt.2024.1416662.

Verstappen D, Pasquier D, Chen Y, Lambin P, Woodruff HC.

Radiomic feature robustness in CT scans affected by fiducial marker induced streak artifacts for patients with hepatocellular carcinoma.

Med Phys. 2024 Nov;51(11):8362-8370. doi: 10.1002/mp.17329.

\*\*\* Trentesaux V, Maiezza S, Bogart E, Le Deley MC, Meyer E, Vanquin L, Pasquier D, Mortier L, Mirabel X.

Stereotactic body radiotherapy as a viable treatment on extracranial oligometastases in melanoma patients: a retrospective multicentric study.

Front Oncol. 2024 Mar 5;14:1322515. doi: 10.3389/fonc.2024.1322515.

Boileau M, Dubois M, Pruvot C, Desmedt E, Templier C, Meyer N, Mirabel X, Mortier L.

Sequential combination of sonic hedgehog inhibitors followed by consolidation radiotherapy in locally advanced basal cell carcinoma.

Clin Exp Dermatol. 2024 Aug 22;49(9):1024-1028. doi: 10.1093/ced/llae068.

Crop F, Robert C, Viard R, Dumont J, Kawalko M, Makala P, Liem X, El Aoud I, Ben Miled A, Chaton V, Patin L, Pasquier D, Guillaud O, Vandendorpe B, Mirabel X, Ceugnart L, Decoene C, Lacornerie T.

Efficiency and Accuracy Evaluation of Multiple Diffusion-Weighted MRI Techniques Across Different Scanners.

J Magn Reson Imaging. 2024 Jan;59(1):311-322. doi: 10.1002/jmri.28869.

Sargos P, Le Guevelou J, Khalifa J, Albiges L, Azria D, de Crevoisier R, Supiot S, Créhange G, Roubaud G, Chapet O, Pasquier D, Blanchard P, Latorzeff I.

The role of radiation therapy for de novo metastatic bladder and renal cancers.

Cancer Radiother. 2024 Feb;28(1):56-65. doi: 10.1016/j.canrad.2023.02.004.

## Divers

Guérin J, Nahid A, Tassy L, Deloger M, Bocquet F, Thézenas S, Desandes E, Le Deley MC, Durando X, Jaffré A, Es-Saad I, Crochet H, Le Morvan M, Lion F, Raimbourg J, Khay O, Craynest F, Giro A, Laizet Y, Bertaut A, Joly F, Livartowski A, Heudel P.

Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer Research.

Int J Environ Res Public Health. 2024 Feb 7;21(2):189. doi: 10.3390/ijerph21020189.

Messelmani T, Le Goff A, Soncin F, Souguir Z, Merlier F, Maubon N, Legallais C, Leclerc E, Jellali R. Coculture model of a liver sinusoidal endothelial cell barrier and HepG2/C3a spheroids-on-chip in an advanced fluidic platform.

J Biosci Bioeng. 2024 Jan;137(1):64-75. doi: 10.1016/j.jbiosc.2023.10.006.